Elicio Therapeutics (ELTX) Shares Outstanding (Weighted Average) (2020 - 2026)

Elicio Therapeutics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 40.63% year-over-year to $18.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.2 million (up 40.63% YoY), and the FY2025 full-year result was $15.3 million, up 25.48% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $18.2 million, up from $15.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $30.0 million in Q1 2022, with the low at $314572.0 in Q2 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $10.1 million across 5 years, with a median of $10.8 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) slumped 98.92% — and 2024, when it surged 3069.93%.
• Elicio Therapeutics' Shares Outstanding (Weighted Average) stood at $315998.0 in 2022, then jumped by 1500.08% to $5.1 million in 2023, then surged by 141.35% to $12.2 million in 2024, then grew by 25.48% to $15.3 million in 2025, then advanced by 18.93% to $18.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $18.2 million (Q1 2026), $15.3 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.